Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Eric Aguiar sold 4,072 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $55.11, for a total value of $224,407.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Eric Aguiar also recently made the following trade(s):
- On Monday, December 16th, Eric Aguiar sold 3,537 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $55.13, for a total value of $194,994.81.
- On Wednesday, November 20th, Eric Aguiar sold 6,729 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $52.20, for a total value of $351,253.80.
- On Friday, November 22nd, Eric Aguiar sold 1,250 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $55.24, for a total value of $69,050.00.
Shares of BHVN stock traded up $0.65 during trading hours on Friday, reaching $53.17. The stock had a trading volume of 725,140 shares, compared to its average volume of 732,680. The firm has a 50-day simple moving average of $52.18 and a 200-day simple moving average of $46.48. Biohaven Pharmaceutical Holding Co Ltd has a twelve month low of $29.17 and a twelve month high of $67.86. The firm has a market capitalization of $2.78 billion, a PE ratio of -8.65 and a beta of 0.47.
Biohaven Pharmaceutical (NYSE:BHVN) last released its quarterly earnings results on Friday, November 1st. The company reported ($2.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.57) by ($0.47). Analysts predict that Biohaven Pharmaceutical Holding Co Ltd will post -7.93 EPS for the current year.
Several equities research analysts recently issued reports on BHVN shares. William Blair reissued a “buy” rating on shares of Biohaven Pharmaceutical in a research report on Tuesday, December 10th. ValuEngine raised shares of Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a report on Saturday, December 7th. Zacks Investment Research lowered shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a report on Monday, October 21st. Piper Jaffray Companies reaffirmed a “buy” rating and set a $100.00 price objective on shares of Biohaven Pharmaceutical in a research report on Tuesday. Finally, Goldman Sachs Group set a $89.00 price objective on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $71.42.
A number of institutional investors have recently made changes to their positions in BHVN. State Street Corp increased its stake in Biohaven Pharmaceutical by 28.8% during the 3rd quarter. State Street Corp now owns 2,044,943 shares of the company’s stock valued at $85,315,000 after buying an additional 456,986 shares during the period. Eventide Asset Management LLC increased its stake in shares of Biohaven Pharmaceutical by 98.5% during the third quarter. Eventide Asset Management LLC now owns 1,634,000 shares of the company’s stock valued at $68,170,000 after acquiring an additional 811,000 shares during the period. Vanguard Group Inc. increased its stake in shares of Biohaven Pharmaceutical by 34.2% during the second quarter. Vanguard Group Inc. now owns 1,154,257 shares of the company’s stock valued at $50,545,000 after acquiring an additional 294,098 shares during the period. Brown Advisory Inc. raised its holdings in Biohaven Pharmaceutical by 60.7% during the second quarter. Brown Advisory Inc. now owns 1,008,046 shares of the company’s stock worth $44,144,000 after purchasing an additional 380,764 shares in the last quarter. Finally, Eagle Asset Management Inc. raised its holdings in Biohaven Pharmaceutical by 0.3% during the third quarter. Eagle Asset Management Inc. now owns 984,335 shares of the company’s stock worth $41,066,000 after purchasing an additional 2,939 shares in the last quarter. 92.83% of the stock is currently owned by hedge funds and other institutional investors.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
Read More: Trading Ex-Dividend Strategy
Receive News & Ratings for Biohaven Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.
